Afatinib (A) Plus Paclitaxel (P) Following Progression on a Monotherapy in Patients (PTS) with Metastatic Non–Small-Cell Lung Cancer (NSCLC) Who Previously Benefited From Erlotinib (E)/Gefitinib (G): a Global Randomised Phase Iii Trial–Lux-Lung 5 (LL5)

Subjects

Subjects :

Oncology
Brachial Plexus Neuritis
medicine.medical_specialty
Randomization
Lung
business.industry
Medizin
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
chemistry.chemical_compound
Gefitinib
medicine.anatomical_structure
Paclitaxel
chemistry
Internal medicine
medicine
In patient
Erlotinib
business
medicine.drug

Details

ISSN :

09237534

Volume :

26

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi.dedup.....63690e1e773d69f4c1dd1e357a5dfc7d

Full Text :

https://doi.org/10.1093/annonc/mdv050.11